Cannabidiol 100 MG/ML [Epidiolex]
600mg
Loading study record…
Loading study record…
The purpose of this study is to determine the impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder on buprenorphine or methadone treatment.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2023-10-05
What this record can show
Results are reported by the registry submitter and preserved exactly. They are not independent verification or a treatment recommendation.
Registry facts
Individuals with opioid use disorder (OUD) demonstrate reward- and stress-related neurocognitive changes compared to individuals without OUD, including cravings for opioids in response to exposure to triggers, tendency to make impulsive and disadvantageous decisions, and a strong attentional bias towards drug-related cues. Together, these deficits are significant contributors to relapse and discontinuation of treatment. Cannabidiol (CBD) has been shown to impact some of these cognitive deficits but studies of CBD among individuals with OUD are mostly lacking. Therefore, this study aims to answer whether CBD has any impact on reward-related neurocognitive deficits in individuals with OUD. If successful, this line of research will lay the groundwork for future studies to evaluate CBD's impact on OUD treatment outcomes.
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Research network
Interventions
600mg
Matching placebo
Source-reported results
Results are reported by the registry submitter and preserved exactly. They are not independent verification or a treatment recommendation.
The primary outcomes is cue-induced cravings (Opioid Craving Scale). This was measured with a single 10-point likert scale asking about cravings, where 0 represented lower levels of craving and 10 indicated higher levels of cravings. This was given at 3 different time points, pre-cue, post-neutral, and post-drug images. Cue-induced craving is the difference between drug cue and pre-cue scores.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Cannabidiol 600mg | 10 | 0.7 | 1.3 |
| Placebo | 10 | 1.1 | 2.0 |
| Cannabidiol 600mg | 10 | 0.9 | 1.1 |
| Placebo | 10 | 2.4 | 1.7 |
| Cannabidiol 600mg | 10 | 0.5 | 1.3 |
| Placebo | 10 | 1.1 | 2.0 |
| Cannabidiol 600mg | 10 | 0.2 | 0.79 |
| Placebo | 10 | 1.3 | 1.9 |
Monetary Choice Questionnaire will be used to calculate impulse decision making. This is a 27-item self-administered questionnaire where participants choose between a smaller, immediate monetary reward and a larger, delayed monetary reward. A participants score is between one of the two endpoints (0.25 or 0.00016). If an individual is more likely to prefer the delayed versus immediate reward, their score is more likely to be closer to the 0.00016 endpoint. Please note the rate of delayed discounting is not the same for each question.
Eligibility
primary outcomes
Time frame: Visit 2 and 3 (at least 1 week apart)
The primary outcomes is cue-induced cravings (Opioid Craving Scale). This was measured with a single 10-point likert scale asking about cravings, where 0 represented lower levels of craving and 10 indicated higher levels of cravings. This was given at 3 different time points, pre-cue, post-neutral, and post-drug images. Cue-induced craving is the difference between drug cue and pre-cue scores.
secondary outcomes
Time frame: Visit 2 and 3 (at least 1 week apart)
Monetary Choice Questionnaire will be used to calculate impulse decision making. This is a 27-item self-administered questionnaire where participants choose between a smaller, immediate monetary reward and a larger, delayed monetary reward. A participants score is between one of the two endpoints (0.25 or 0.00016). If an individual is more likely to prefer the delayed versus immediate reward, their score is more likely to be closer to the 0.00016 endpoint. Please note the rate of delayed discounting is not the same for each question.
Time frame: Visit 2 and 3 (at least 1 week apart)
Iowa Gambling Task will be used to assess impulsive decision-making. The larger the number, the more "safer" options were chosen. This is measured by taking the total number of "risky" choices and subtracting it from the "less risky" choices. The lower the number, the more "high risky" options were chosen. If participants chose the less risky option, they received a positive point, if individuals picked the riskier choice, they received a negative point. Negative values indicate a participant chose more riskier decisions than less-risky, whereas positive values indicate participants chose the less riskier decision more often. The lowest score an individual could receive is -100 (very risk) to 100 (least risky).
Time frame: Visit 2 and 3 (at least 1 week apart)
Visual probe task will be used to assess attentional bias to drug-related cues. Opioid-related and neutral images will be used. Each trial will begin with a fixation point lasting 500ms. A pair of images then will appear on the left and right of the screen for either a short (200ms) or long (500ms) stimulus duration to assess automatic orientating and controlled attention processing, respectively. Image pairs will be replaced by a probe in the location of either the opioid-related or neutral image. The probe will remain until the participant responds to identify the probe orientation by pressing the response keys as quickly as possible. Attentional bias is calculated as the difference in reaction time (RT) between when the probe replaced the neutral compared with the opioid-related images (i.e. RTneutral - RTopioid). Therefore the more positive the number, the less attentional bias toward drug cue, and a negative number represents more attentional bias toward the drug cue.
Time frame: Visit 2 and 3 (at least 1 week apart)
Physiologic and subjective stress will be assessed. Stress-reactivity was measured by participants mirror tracing an image on a compute screen where a loud beeping noise would occur if a participant took too long or went outside the lines. It's measured in ms and the longer someone stayed on the task, the better ability they have to react stress.
Publications
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Cannabidiol 600mg | 10 | 0.020 | 0.024 |
| Placebo | 10 | 0.039 | 0.075 |
Iowa Gambling Task will be used to assess impulsive decision-making. The larger the number, the more "safer" options were chosen. This is measured by taking the total number of "risky" choices and subtracting it from the "less risky" choices. The lower the number, the more "high risky" options were chosen. If participants chose the less risky option, they received a positive point, if individuals picked the riskier choice, they received a negative point. Negative values indicate a participant chose more riskier decisions than less-risky, whereas positive values indicate participants chose the less riskier decision more often. The lowest score an individual could receive is -100 (very risk) to 100 (least risky).
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Cannabidiol 600mg. | 10 | 2.2 | 9.3 |
| Placebo | 10 | -6.4 | 18.9 |
Visual probe task will be used to assess attentional bias to drug-related cues. Opioid-related and neutral images will be used. Each trial will begin with a fixation point lasting 500ms. A pair of images then will appear on the left and right of the screen for either a short (200ms) or long (500ms) stimulus duration to assess automatic orientating and controlled attention processing, respectively. Image pairs will be replaced by a probe in the location of either the opioid-related or neutral image. The probe will remain until the participant responds to identify the probe orientation by pressing the response keys as quickly as possible. Attentional bias is calculated as the difference in reaction time (RT) between when the probe replaced the neutral compared with the opioid-related images (i.e. RTneutral - RTopioid). Therefore the more positive the number, the less attentional bias toward drug cue, and a negative number represents more attentional bias toward the drug cue.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Cannabidiol 600mg | 10 | -80.4 | 298.8 |
| Placebo | 10 | 100.3 | 123.5 |
| Cannabidiol 600mg | 10 | 145.2 | 392.3 |
| Placebo | 10 | -93.1 | 268.5 |
Physiologic and subjective stress will be assessed. Stress-reactivity was measured by participants mirror tracing an image on a compute screen where a loud beeping noise would occur if a participant took too long or went outside the lines. It's measured in ms and the longer someone stayed on the task, the better ability they have to react stress.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Cannabidiol 600mg | 10 | 59.00 | 37.75 |
| Placebo Session | 10 | 99.83 | 100.78 |
For this outcome, participants received a salivary cortisol test prior to, immediately after, and 20 minutes after the cue-reactivity paradigm. Lower levels indicate lower levels of salivary cortisol in the sample.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Cannabidiol 600mg | 10 | 0.0855 | 0.0579 |
| Placebo Session | 10 | 0.1542 | 0.179 |
| Cannabidiol 600mg | 10 | 0.0745 | 0.272 |
| Placebo Session | 10 | 0.0816 | 0.045 |
| Cannabidiol 600mg | 10 | 0.0828 | 0.060 |
| Placebo Session | 10 | 0.0806 | 0.0429 |
| Milestone | Cannabidiol 600mg First, Placebo Second | Placebo First, Cannabidiol 600mg Second |
|---|---|---|
| STARTED | 7 | 8 |
| Baseline | 7 | 8 |
| First Intervention | 5 | 5 |
| Second Intervention | 5 | 5 |
| COMPLETED | 5 | 5 |
| NOT COMPLETED | 2 | 3 |
Time frame: Visit 2 and 3 (at least 1 week apart)
For this outcome, participants received a salivary cortisol test prior to, immediately after, and 20 minutes after the cue-reactivity paradigm. Lower levels indicate lower levels of salivary cortisol in the sample.